OBiO Technology, a world leading contract development and manufacturing organisation (CDMO) for cell and gene therapy, has launched the 'Centre for Clinical Evaluation and Translation of Advanced Therapies for Pediatric Rare and Genetic Diseases' ('Clinical Evaluation and Translation Centre') at the 2024 Global Rare Disease Research Symposium and the 2nd China Rare Disease Research and Translational Medicine Conference.

This centre, jointly initiated by Shanghai Children's Medical Center, Zhejiang Hope for Rare Foundation, and OBiO Technology aims to promote clinical research and therapeutic innovation for pediatric rare and genetic diseases.

The Clinical Evaluation and Translation Centre is an open platform welcoming enterprises, universities, research institutes, foundations, and individuals involved in advanced therapies. The centre aims to leverage regional policy advantages to build a cell and gene therapy industry cooperation platform, focusing on technological R&D innovation, clinical application, industry-academia-research cooperation, resource sharing, and collaborative innovation to enhance the technological and industrial competitiveness of cell and gene therapy.